New global project fighting anti-microbial resistance begins

ID-CARE Team Members joined the kick-off of a new scientific project last week: FAIR - public health value, eFfectiveness, Analysis and modellIng of Reserve antibiotics.

On 11th June, the ID-CARE team held the official Kick-off Meeting of the FAIR Project, funded by the Global Antibiotic Research and Development Partnership (GARDP). The FAIR project will be developed on a 3-year timeline, from June 2025 to May 2028, and will represent a brilliant collaboration opportunity between diverse teams in various academic institutions. Moreover, it is expected to bring exciting networking chances, along with a very high-impact publication output.

FAIR, which stands for “public health value, eFfectiveness, Analysis and modellIng of Reserve antibiotics”, will be coordinated by the ID-CARE team from the University of Verona, and will see the participation of partners from Germany (University of Bonn), India (Christian Medical Centre of Vellore), South Africa (University of Cape Town) and Sweden (Umeå University). In particular, the ID-CARE group involved in FAIR will be led by Prof. Evelina Tacconelli and will encompass infectious disease physicians, public health specialists, epidemiologists and biostatisticians.

The FAIR project aims at modelling the impact of the introduction of antibiotics belonging to the “Reserve” group according to the World Health Organisation’s AWaRe classification, i.e. the last-resort drugs that should be used with particular attention and in highly specific cases only. The model will stem from integrating an assessment of the clinical impact of Reserve antibiotics in treating Gram-negative infections and a cost-effectiveness analysis that considers price thresholds and public health value, and will be validated on real-world data coming from different, representative country scenarios.

The whole project will start from the results of many ongoing international projects related to antimicrobial resistance (e.g. BLOOMY, CLEARER, COHERENCE, EPI-Net, REVERSE, WHO Bacterial Priority List), to create a compound database including the most updated primary and secondary evidence. Such a dataset will provide ground for building reliable models whose output can support regulatory agencies and public health stakeholders in improving patient outcomes, by reducing mortality and preserving the effectiveness of antibiotics.

Find out more about the project here: https://www.id-care.net/projects/fair